|
Allelic distribution of HLA-C in patients and controls |
|||
| HLA-C allele |
Psoriasis (n = 45) |
PsA (n = 100) |
Controls (n = 177) |
|
|
|||
| Cw*0102 |
5 (11) |
10 (10) |
13 (7) |
| Cw*0202 |
4 (9) |
8 (8) |
9 (5) |
| Cw*0303 |
3 (7) |
11 (11) |
19 (11) |
| Cw*0304 |
2 (4) |
4 (4) |
15 (8) |
| Cw*0401 |
7 (15) |
23 (23) |
50 (28) |
| Cw*0501 |
4 (9) |
9 (9) |
30 (17) |
| Cw*0602 |
26 (58)a |
58 (58)b |
32 (18) |
| Cw*0701 |
9 (20) |
19 (19)c |
54 (31) |
| Cw*0702 |
7 (15) |
17 (17) |
45 (25) |
| Cw*0802 |
2 (4) |
3 (3)d |
17 (10) |
| Cw*1203 |
3 (7) |
3 (3) |
6 (3) |
| Cw*1402 |
1 (2) |
4 (4) |
9 (5) |
| Cw*1502 |
4 (9) |
5 (5) |
13 (7) |
| Cw*1601 |
2 (4) |
4 (4) |
15 (8) |
| Cw*1602 |
- |
- |
2 (1) |
|
HLA, human leukocyte antigen; PsA, psoriatic arthritis. Results in parentheses are percentages. aOdds ratio (OR) 6.2 (95% confidence interval (CI) 3.1 to 12.5; p < 0.0001); bOR 6.2 (95% CI 3.6 to 10.8; p < 0.0001); cOR 0.5 (95% CI 0.3 to 0.9; p = 0.04); dOR 0.3 (95% CI 0.08 to 1.00; p = 0.05). | |||
Queiro et al. Arthritis Research & Therapy 2006 8:R185 doi:10.1186/ar2097 |
|||